Products
Lanadelumab was approved as an injectable in the US and EU in 2018 and in many countries in 2019 (Takhzyro).
Structure and properties
Lanadelumab is a recombinant human IgG1κ monoclonal antibody with a molecular mass of 146 kDa. It is produced by biotechnological methods.
Effects
The effects of lanadelumab (ATC B06AC05) are based on binding to plasma kallikrein, resulting in inhibition of its proteolytic activity. The protease plasma kallikrein forms bradykinin, a potent vasodilator that increases vascular permeability and causes swelling and pain in patients with hereditary angioedema. In this rare disorder, the regulation of plasma kallikrein is impaired, resulting in uncontrolled activity. The mean half-life is 14 days.
Indications
For long-term prophylaxis of attacks of hereditary angioedema.
Dosage
According to the SmPC. The drug is injected subcutaneously every two or four weeks.
Contraindications
- Hypersensitivity
For complete precautions, see the drug label.
Interactions
Corresponding studies have not been performed.
Adverse effects
The most common potential adverse effects include injection site reactions and pain.